Crohn’s Disease Treatment: Standard Care and What Stem Cell Research Actually Shows

Crohn’s disease is a chronic inflammatory bowel disease with no cure, managed primarily through medication (aminosalicylates, corticosteroids, immunomodulators, and biologics) and, when needed, surgery. Stem cell research for Crohn’s disease has produced the most advanced regulatory milestone of any autoimmune condition on this site: a mesenchymal stem cell therapy (darvadstrocel, brand name Alofisel) was approved by the European Medicines Agency in 2018 specifically for complex perianal fistulas in Crohn’s disease. However, the manufacturer voluntarily withdrew it from the EU market in December 2024, citing that real-world data no longer supported its continued use despite the original positive trial results. This is an important, current piece of context for anyone researching stem cell therapy for Crohn’s disease.

Crohn’s disease is a type of inflammatory bowel disease (IBD) in which the immune system mistakenly attacks the digestive tract, most commonly the small intestine and colon, causing chronic inflammation, ulceration, and in some cases structural damage such as strictures or fistulas. Symptoms typically include abdominal pain, diarrhea, fatigue, and weight loss, with a pattern of flares and remission over time.

• Aminosalicylates — used for mild inflammation, primarily in the colon
• Corticosteroids — used to control flares, generally for short-term use due to side effects with prolonged use
• Immunomodulators — help reduce immune system activity over the longer term
• Biologic therapies — target specific inflammatory pathways and are commonly used for moderate to severe disease
• Surgery — used when medication doesn’t adequately control the disease, or to address complications like strictures, abscesses, or fistulas

Complex perianal fistulas — abnormal connecting tunnels that can form near the anus — are a particularly difficult complication, since conventional medical and surgical treatment for them has historically had modest success rates and high recurrence.

This is genuinely one of the more advanced areas of regenerative medicine research among autoimmune conditions, so it’s worth walking through the evidence in order:

The approval: In 2018, the European Medicines Agency approved darvadstrocel (Alofisel), an allogeneic mesenchymal stem cell therapy derived from adipose tissue, specifically for complex perianal fistulas in adult Crohn’s patients whose fistulas hadn’t adequately responded to at least one conventional or biologic therapy. The approval was based on the Phase III ADMIRE-CD trial, which showed statistically significant improvement in combined remission at 24 weeks compared to a control group, with follow-up data suggesting the benefit was maintained at 52 weeks. This was the first allogeneic stem cell therapy approved in Europe for any medical condition — a genuinely significant regulatory milestone.

The withdrawal: In December 2024, Takeda (which had acquired the therapy) announced it was voluntarily working with the EMA to withdraw Alofisel’s marketing authorization in the EU, stating that despite conflicting results across their data, the clinical benefit was no longer considered sufficient to justify its continued use. This is an important update: it shows that even a therapy that clears formal regulatory approval based on a positive pivotal trial can later be reassessed and withdrawn when broader, real-world evidence doesn’t consistently support the original result. This is exactly the kind of outcome that underscores why investigational and even approved regenerative therapies require ongoing evidence review, not just an initial approval.

Other ongoing research: Separately from the Alofisel story, mesenchymal stem cell approaches continue to be studied for Crohn’s disease more broadly — including a trial evaluating allogeneic bone marrow-derived MSCs (remestemcel-L) delivered by targeted endoscopic injection for medically refractory Crohn’s colitis. A small pilot study also examined adipose-derived stem cells specifically for perianal fistula treatment. These represent ongoing, earlier-stage research rather than established treatments.

Case-level evidence: A published case report described symptom improvement in a single patient with long-standing Crohn’s disease following Stem Cell Educator therapy, a distinct immune-modulating approach. A single case report is the weakest form of clinical evidence and should not be generalized into an expectation of similar results for others.

Given this evidence landscape, our position is straightforward: stem cell therapy for Crohn’s disease, including for complex perianal fistulas, should currently be considered investigational rather than an established, universally available treatment — even accounting for the historical EU approval, given its subsequent withdrawal. We think it’s important for patients researching this topic to understand both the genuine promise this research has shown and the reality that even approved therapies can be withdrawn on further evidence review. Any discussion of regenerative approaches happens alongside, not instead of, your existing gastroenterology care.

• Common types of autoimmune diseases — full guide
• Stem cell treatment for Crohn’s disease in India
• Stem cell treatment for ulcerative colitis
• Safety & Guarantees FAQ

Have questions about your specific case? Book a free case review for an honest conversation about current evidence, including the most recent developments, and your options going forward.